ReviewPathologie (Heidelberg, Germany)2025
[Cholangiocarcinoma : Histopathological diagnosis, classification and molecular diagnostics-an update].
Review in Pathologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term cholangiocarcinoma covers various malignant epithelial neoplasms with biliary differentiation. The aim of this article is to provide an update with new findings and developments on the etiology, pathogenesis, diagnosis, classification, and molecular diagnostics of intra- and extrahepatic cholangiocarcinomas based on the last review published in this journal in 2020. The basis is the currently available specialist literature, lectures, and discussions at congresses as well as our own findings.Cholangiocarcinomas are morphologically and molecularly diverse malignant epithelial neoplasms that can develop ubiquitously in the biliary tract. As there is a broad histological and immunohistochemical overlap with the frequent metastases in the liver, the definitive diagnosis should only be made in a clinical context. According to macroanatomical criteria, cholangiocarcinomas are subclassified into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) tumors. In the case of iCCA, a distinction can be made in particular between small duct type tumors (SD-iCCA) and large duct type tumors (LD-iCCA). LD-iCCA are morphologically and molecularly practically equivalent to extrahepatic CCA (eCCA, including pCCA and dCCA), while SD-iCCA originate from the small bile ducts or precursor cells and often exhibit druggable molecular alterations. Cholangiocarcinogenesis is now better described by morphomolecular studies of precursor lesions and the various precursor lesions can be assigned not only according to anatomical classification but also to distinct etiologies. A precise classification of these neoplasms is therefore essential, especially with regard to the use of established and the development of novel targeted therapeutic approaches.
Indexed as
Identifiers
40864260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.